These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 4350685)

  • 61. Type IV hyperlipoproteinemia. Clofibrate without dietary therapy.
    Zelis R; Amsterdam EA; Spann JF; Mason DT
    JAMA; 1972 Oct; 222(3):326-8. PubMed ID: 4566727
    [No Abstract]   [Full Text] [Related]  

  • 62. Effects of the combination of nicotinic acid and propranolol in very low doses on blood lipids in man.
    Avogaro P; Capri C; Cazzolato G; Pais M; Trabuio GF
    Atherosclerosis; 1974; 20(2):395-400. PubMed ID: 4369975
    [No Abstract]   [Full Text] [Related]  

  • 63. [Typology of the hyperlipoproteinemias in ischemic heart disease].
    Zakharova VN; Afanas'eva ON; Andrushchenko ES; Naumova LV; Zarudina IN
    Kardiologiia; 1977 Dec; 17(12):105-8. PubMed ID: 202776
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Combined para-aminosalicylic acid and dietary therapy in long-term control of hypercholesterolemia and hypertriglyceridemia (Types IIa and IIb hyperlipoproteinemia).
    Kuo PT; Fan WC; Kostis JB; Hayase K
    Circulation; 1976 Feb; 53(2):338-41. PubMed ID: 173477
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Hypolipemic effect of diosponine in ischemic heart disease depending on the type of hyperlipoproteinemia].
    Zakharov VN
    Kardiologiia; 1977 Jun; 17(6):136-7. PubMed ID: 197285
    [No Abstract]   [Full Text] [Related]  

  • 66. Combined hyperlipoproteinemia. Evidence for a new lipoprotein phenotype.
    Rose HG; Kranz P; Weinstock M; Juliano J; Haft JI
    Atherosclerosis; 1974; 20(1):51-64. PubMed ID: 4376406
    [No Abstract]   [Full Text] [Related]  

  • 67. Comparative study of several hypolipidemic agents related to clofibrate.
    Beaumont V; Buxtorf JC; Jacotot B; Beaumont JL
    Atherosclerosis; 1974; 20(2):141-53. PubMed ID: 4369878
    [No Abstract]   [Full Text] [Related]  

  • 68. Hyperlipoproteinemia: problems in diagnosis and challenges posed by the "type III" disorder.
    Havel RJ
    Ann Intern Med; 1975 Feb; 82(2):273-4. PubMed ID: 163610
    [No Abstract]   [Full Text] [Related]  

  • 69. Effects of SU-13437 on serum lipids in hyperlipoproteinemic patients.
    Weiss P; Dujovne CA; Margolis S; Lasagna L; Bianchine JR
    Clin Pharmacol Ther; 1970; 11(1):90-6. PubMed ID: 4903694
    [No Abstract]   [Full Text] [Related]  

  • 70. Lowering of serum cholesterol and triglyceride by para-aminosalicylic acid in hyperlipoproteinemia. Studies in patients with types II-A and II-B.
    Barter PJ; Connor WE; Spector AA; Armstrong M; Connor SL; Newman MA
    Ann Intern Med; 1974 Nov; 81(5):619-24. PubMed ID: 4609028
    [No Abstract]   [Full Text] [Related]  

  • 71. Cholestyramine in type II hyperlipoproteinemia. A double-blind trial.
    Levy RI; Fredrickson DS; Stone NJ; Bilheimer DW; Brown WV; Glueck CJ; Gotto AM; Herbert PN; Kwiterovich PO; Langer T; LaRosa J; Lux SE; Rider AK; Shulman RS; Sloan HR
    Ann Intern Med; 1973 Jul; 79(1):51-8. PubMed ID: 4578640
    [No Abstract]   [Full Text] [Related]  

  • 72. Studies of plasma viscosity in primary hyperlipoproteinaemia.
    Leonhardt H; Arntz HR; Klemens UH
    Atherosclerosis; 1977 Sep; 28(1):29-40. PubMed ID: 199202
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Principles of drug therapy of hyperlipidemic xanthomatous diseases.
    Zöllner N
    Nutr Metab; 1973; 15(1):144-50. PubMed ID: 4576164
    [No Abstract]   [Full Text] [Related]  

  • 74. Effect of the extractive heparinoid, glucuronylglucosaminglycan sulfate (3-GS), on human plasma lipids.
    Avogaro P; Bittolo BG; Taroni GC; Cazzolato G; Belussi F
    Pharmacol Res Commun; 1977 Nov; 9(10):977-86. PubMed ID: 203952
    [No Abstract]   [Full Text] [Related]  

  • 75. Treatment of type II hyperlipoproteinemia with d-thyroxine.
    Rakow AD; Klor HU; Kuter E; Ditschuneit HH; Ditschuneit H
    Atherosclerosis; 1976 Sep; 24(3):369-80. PubMed ID: 971340
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Correction of hypercholesterolemia and dyslipoproteinemia by plasmapheresis in patients with stenocardia resistant to drug therapy].
    Orlov VN; Lekokhmakher SS; Porunova AK; Dobashina AN; Gavrilov AO
    Kardiologiia; 1988 Nov; 28(11):74-8. PubMed ID: 3230781
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Type IV and IIb hyperlipoproteinemia and the HLA system.
    Raffoux C; Pointel JP; Sauvanet JP; Drouin P; Janot C; Streiff F; Debry G
    Tissue Antigens; 1978 Sep; 12(3):212-4. PubMed ID: 83019
    [No Abstract]   [Full Text] [Related]  

  • 78. [Lipid composition of lipoproteins and excretion of 17-ketosteroids in coronary arteriosclerosis].
    Titov VN; Gerasimova EN; Bodrova EA
    Kardiologiia; 1976 Feb; 16(2):49-55. PubMed ID: 184338
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Dose-response to tibric acid: a new hypolipidemic drug in type IV hyperlipoproteinemia.
    Bielmann P; Brun D; Moorjani S; Gagné C; Lupien P; Tétreault L
    Clin Pharmacol Ther; 1975 May; 17(5):606-11. PubMed ID: 165029
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Fasting serum bile acid levels in the primary hyperlipoproteinemias.
    Korman MG; Ellefson RD; Hofmann AF
    Mayo Clin Proc; 1975 Feb; 50(2):76-8. PubMed ID: 163941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.